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AbstrAct
Currently there are no FDA approved targeted therapies for Triple Negative Breast 
Cancer (TNBC). Ongoing clinical trials for TNBC have focused primarily on targeting the 
epithelial cancer cells. However, targeted delivery of cytotoxic payloads to the non-
transformed tumor associated-endothelium can prove to be an alternate approach that 
is currently unexplored. The present study is supported by recent findings on elevated 
expression of stromal galectin-1 in clinical samples of TNBC and our ongoing findings 
on stromal targeting of radiation induced galectin-1 by the anginex-conjugated arsenic-
cisplatin loaded liposomes using a novel murine tumor model. We demonstrate inhibition 
of tumor growth and metastasis in response to the multimodal nanotherapeutic 
strategy using a TNBC model with orthotopic tumors originating from 3D tumor tissue 
analogs (TTA) comprised of tumor cells, endothelial cells and fibroblasts. The ‘rigorous’ 
combined treatment regimen of radiation and targeted liposomes is also shown to be 
well tolerated. More importantly, the results presented provide a means to exploit 
clinically relevant radiation dose for concurrent receptor mediated enhanced delivery 
of chemotherapy while limiting overall toxicity. The proposed study is significant as it 
falls in line with developing combinatorial therapeutic approaches for stroma-directed 
tumor targeting using tumor models that have an appropriate representation of the 
TNBC microenvironment.
IntroductIon
Breast cancer (BC) is the second leading cause of 
death in women. Of those diagnosed with breast cancer, 
15–20% are classified as triple negative breast cancer 
(TNBC) [1, 2] prevalent in women with African American 
ethnicity and younger age [3–5]. TNBC is a heterogeneous 
subtype, that is histopathologically diagnosed based on the 
characteristics of “triple negativity” defined by the lack 
of expression or overexpression of the “three receptors’: 
estrogen receptor (ER), progesterone receptor (PR) and 
the epidermal growth factor receptor type 2 (HER2) [6]. 
More aggressive than other forms of breast cancer, TNBC 
presents an early, truculent visceral metastases, a short 
life expectancy with poor prognosis and few effective 
treatment options [3, 7–9]. The standard of care for TNBC 
patients’ remains to be traditional chemotherapy, surgery 
and radiation. Unlike the receptor driven breast cancers, 
the oncologists do not have any FDA approved targeted 
therapies from the existing drug arsenal for advanced 
stage of TNBC that presents an average progression 
free survival of 12 months, which is far less than the 
other subtypes of BC. Identifying specific targets for 
more effective and promising therapies for treatment of 
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TNBC has therefore become a major clinical challenge. 
An improved understanding of the biology of TNBC has 
led to the discovery of therapeutic targets for TNBC, 
such as the Notch signaling pathway (RO-4929097) [10], 
Wnt/b-catenin pathway (Salinomycin) [11], DNA repair 
pathways (PARP1 inhibitors: Iniparib, Olaparib) [12, 13], 
Overexpressed epidermal growth factor (EGFR inhibitors: 
Gefltinib, cetuximab) [14, 15], P13/Akt/mammalian 
target of rapamycin (mTOR) activation (mTOR inhibitors 
(Everolimus) [16] and TGF-β signaling pathway 
(TGFBR1 inhibitor: LY2157299) [17]. However, the 
molecular heterogeneity of TNBC [18, 19] may explain 
for the marginal benefits in clinical trials with these 
targeted therapies that are majorly focused on targeting 
single pathways in the epithelial cancer cells, a critical 
contributor to the TNBC heterogeneity [20]. The limited 
success of the molecularly targeted therapies in TNBC 
thus, highlights the ongoing importance for cytotoxic 
therapy and the need for ‘think-out of the box’ approaches 
to develop novel treatment strategies augmenting the 
current treatment options for TNBC.
Therapeutic options to target the tumor stroma 
are limited with the most exploited exception being 
bevacizumab (Avastin, Roche), a monoclonal antibody 
that targets vascular endothelial growth factor (VEGF) 
and inhibits tumor angiogenesis [21]. However, its use 
in the treatment of TNBC has not been encouraging 
and therefore was restricted by the FDA in late 2011 
for subsequent use in the treatment of metastatic breast 
cancer [22]. A carbohydrate binding protein, galectin-1, 
which plays a pivotal role in tumor growth and cancer 
progression including invasion, angiogenesis and 
metastasis is a propitious alternative for stromal targeting 
of the non-transformed tumor associated-endothelium. 
Studies, including our own, have demonstrated the 
potential of galectin-1 as a therapeutic target by 
identifying the overexpression of galectin-1 in various 
human cancers and enrichment in tumor stroma [23, 24]. 
In addition, we have reported a further induction of 
galectin-1 expression in tumor stroma as a response to 
radiation therapy, suggesting that targeting galectin-1 may 
synergize with radiation therapy [23–25]. A number of 
novel compounds and approaches to block galectin-1 or its 
activity are currently being evaluated [23]. The synthetic 
antiangiogenic peptide, anginex, has been shown to bind 
specifically to the galectin-1 receptor and delay the tumor 
growth [26–28]. Anginex is an antiangiogenic 33 amino 
acid beta sheet peptide [29–31] that specifically binds and 
inhibits the function of galectin-1 receptor [27, 32–34]. 
While unable to completely block tumor growth, anginex 
can serve as an excellent ligand for targeted delivery of 
liposomal cytotoxic payloads to the tumor endothelium. 
However, developing nanotherapeutic regimens that 
target the tumor stroma implicitly demand reliable tumor 
models that replicate the stromal characteristics of the 
human cancer. Using a murine in vitro/in vivo TNBC 
tumor model system with galectin-1 enriched stroma we 
have reported that conjugation of anginex to liposomes 
enables preferential targeting of the unique mix of dual 
chemotherapy released at the irradiated tumor endothelium 
in a controlled manner over time, beyond that expected 
from enhanced tumor permeability and retention [25]. 
This novel therapeutic approach is designed to destabilize 
the tumor microenvironment which sensitizes and primes 
the tumor cells for cell death, maximizing the therapeutic 
gain of the antitumor strategy in selective and effective 
inhibition of tumor growth and metastasis in contrast 
to conventional systemic approaches. In this study we 
establish the overexpression of galectin-1 in the TNBC 
stroma using the murine tumor model system with an 
appropriate representation of the tumor microenvironment 
developed in our laboratory we have investigated the 
therapeutic efficacy as well as the biocompatibility of 
the radiation enhanced galectin-1 targeting with anginex 
conjugated arsenic trioxide (ATO) and cisplatin loaded 
liposomes to the TNBC microenvironment. 
rEsuLts
Similarity in the expression profile of galectin-1 
to VEGF-A in ductal carcinoma of the breast 
indicate it’s potential as a candidate for stroma-
directed molecular targeting
The primary objective of targeted drug nanoparticle 
delivery is to isolate the disease in vivo against the 
background of the normal functioning tissue without 
disrupting or altering usual physiologic processes. The 
task of developing such a receptor-targeted nanoparticle 
delivery is particularly challenging as it depends upon 
identifying a biomarker or disease characteristic that can 
be ‘targeted’ to achieve the goal. There is compelling 
evidence for galectin-1 as an important protein in 
cancer biology that is enriched in the tumor- associated 
neovascular endothelium [24, 27, 32, 33]. We also 
explored the data from The Human Protein Atlas for the 
expression of galectin-1 in ductal carcinomas of women 
between 27–40 years of age (Figure 1A). Statistical 
evaluation of the immunohistochemistry revealed 
significantly increased expression of galectin-1 in 
tumor tissues as compared to the normal breast tissues 
(Figure 1B). Enlarged images of the ductal carcinoma 
tissue sections (20×) demonstrated the stromal enrichment 
of galectin-1 (Figure 1B). Furthermore, this difference 
in the expression of galectin-1 between normal versus 
the ductal carcinoma tissues of patients was found to 
be comparable to the expression of vascular endothelial 
growth factor (VEGF-A) in the same or similar tissues. 
VEGF-A, a multifunctional cytokine secreted by human 
tumors, is implicated with poor prognosis in breast cancer 
[35, 36]. One of the major challenges in developing a 
molecular targeted therapy is in identifying a biomarker 
significantly overexpressed in the tumor tissue, not just 
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in comparison to the corresponding normal tissue but in 
tissue of other normal organs. The data from the Human 
Protein Atlas in Figure 2 demonstrates that while galectin-1 
is expressed in organs other than the breast, the quantitation 
of representative images indicated the galectin-1 expression 
to be notably higher in the tumor tissues in comparison to 
the other normal tissues (Figure 2).
Elevated expression of stromal galectin-1 in 
clinical samples of TNBC 
Galectin-1 staining in normal breast tissue was 
identified using immunohistochemical analysis, and there 
appeared to be a low level of membrane staining primarily 
involving the normal ductal and lobular units, with no 
significant staining of the myoepithelial or adipose tissue 
(black arrows) (Figure 3A and 3C). The median H score for 
Galectin-1 for benign tissue was 63.12. In contrast, tumor 
staining was more uniform with a more intense membrane 
staining pattern in both the ductal and lobular units. The 
pronounced staining in the tumors was in the intervening 
myoepithelial and stromal tissue, with a median H Score 
of 186.1 (Figure 3A–3B).  This suggests a significant 
difference in the level of galectin-1 expression between 
benign and tumor tissue that could be manipulated as a 
target for tumor specific drug delivery. Histopathology 
of the tumor and benign tissue sections from the TNBC 
patient samples was evidenced by the hematoxylin and 
eosin (H&E) staining (Supplementary Figure S1).
Figure 1: Elevated levels of galectin-1 in human tissues of ductal carcinoma compared to the normal breast tissue 
resemble the expression profile of VEGF-A. (A) Spot images of human breast cancer (ductal carcinoma) and normal breast tissues 
1 mm in diameter of women 27–40 years in age stained with galectin-1 antibody (Sigma) [Upper panel] and VEGF antibody (Santa Cruz 
Biotech.) [Lower panel]. (b) Quantitation of image scans (Aperioscope) demonstrating higher % of positive staining for both galectin-1 and 
VEGF-A in ductal carcinoma versus normal breast tissue with *p < 0.0001 and **p < 0.05 respectively (mean ± SE; n = 3 samples/group). 
(c) 20X magnification of ductal carcinoma sections in (A) immunoprobed for galectin-1 demonstrating its stromal enrichment (Brown). 
Tumor cells stain blue (DAPI). Data were provided by the human protein atlas database. Scale bar = 100 μm.
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Figure 2: The differential expression profile of galectin-1 in various human tissues compared to ductal carcinoma. (A) 
Representative spot images of six types of tissues 1 mm in diameter as indicated were probed (Brown) for the expression of galectin-1 
(Sigma) were compared to tumor tissue of ductal carcinoma stained for galectin-1. Data were provided by the human protein atlas database 
(http://www.proteinatlas.org/). (b) Galectin-1 staining was quantitated by APERIO® ImageScope and scored using the H-score approach 
that combines the pixel intensity with the percentage of tissue as described in the methods and graphically represented. (N = 3, *p < 0.005 
or **p < 0.05, for tissues from the tumor compared to that from other organs).
Figure 3: Galectin-1 overexpression in clinical samples of triple negative breast cancer (TNBC) patients. (A) 
Immunohistochemistry of six cases of TNBC matched with the corresponding normal breast tissues for galectin-1. The tissue sections 
were stained with anti-galectin-1 antibody (sigma) and counterstained with Hematoxylin and Eosin (Supplementary Figure S1) at 100X 
magnification. Scale bar = 25 μm (b) Galectin-1 staining in each histological section of benign and tumor tissues of the six TNBC patients 
was scored using the H-score approach as described in the methods and graphically represented. The percentage of tissue stained was 
quantitated by APERIO® ImageScope (N = 6, *p = 0.0002 for tumor tissue compared to the benign tissue). (c) Representative images 
of benign and primary tumor tissue probed for galectin-1. While the tumor cells stained weakly (blue/light brown), the tumor associated 
stroma stained strongly for galectin-1 (brown) in the tumor tissue. The myoepithelial cells/clusters and ductal/lobular units in the benign 
breast tissue also stained strongly for galectin-1 (black arrows) but the staining was restricted to distinct foci. Scale bar = 50 μm. 
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Radiation exposure augments the expression 
of galectin-1 in the murine TNBC model 
developed from orthotopic implant of 3D ‘Tumor 
tissue analog’ (TTA) in nude mice that better 
represents the malignant stroma
We have demonstrated the usefulness of the 3D 
TNBC model in in vivo setting by implantation of the 
TTA in the mammary fat pad of nude mice [24, 25]. This 
preclinical tumor model incorporates aspects of the tumor 
microenvironment and the neovascular architecture, 
critical for evaluating nanoparticles and stroma-directed 
molecular targeting. Our studies have also elucidated the 
radiation-induced galectin-1 surge to be more pronounced 
in the murine TNBC model developed from orthotopic 
implants of TTA comprised of tumor cells, endothelial 
cells and fibroblasts than the orthotopic implants of tumor 
cell only–spheroids [25]. Using the same murine TNBC 
model in this study we compare the galectin-1 expression 
between benign breast, tumor and irradiated tumor tissue 
originating from TTA implants in the mammary fat pad 
of nude mice (Figure 4A and Supplementary Figure S2). 
The H-scores for galectin-1 expression were found to 
be significantly higher in the irradiated tumor tissue in 
comparison to the non-irradiated or benign breast tissue 
(Figure 4B).
Sensitivity to ATO and cisplatin cytotoxicity in 
cell types is associated with p53 phosphorylation
FDA approved, Metal-based drugs such as ATO 
and cisplatin administered at high concentrations for 
effective tumor cell killing often present dose-limiting side 
effects. However, their encapsulation in nanoliposomes 
bound to receptors for specific cell targeting allows 
for their prudent use in improvement of anti-cancer 
efficacy. Molecular profiling with antibody arrays and 
the ingenuity pathway analysis in our earlier studies 
indicate the enhanced activation/phosphorylation of 
proteins associated with the apoptotic or stress signaling 
in response to radiation enhanced targeting of arsenic and 
cisplatin loaded liposomes in 3D murine TTA and their 
orthotopic implants to occur via phosphorylation of the 
functional p53 in endothelial cells [25]. In this study have 
designed an experiment to demonstrate a similar effect in 
the sensitivity of two different human cell types to arsenic 
and cisplatin. MDA-MB-231, a typical human TNBC cell 
line, fails to achieve an IC50 at cisplatin concentration 
of 30 µM [18]. Similar studies with ATO demonstrate 
a 12–15 µM IC50 for MDA-MB-231 cells [37, 38]. 
Figure 5 demonstrates a significant decrease in the 
expression of intact poly ADP-ribose polymerase (PARP) 
(116 kda), indicative of more cell death, in endothelial 
cells (HUVEC) but not the MDA-MB-231 TNBC cells 
incubated at much lower concentrations of cisplatin 
(20 µM) and ATO (5 µM). Literature suggests that the 
constitutively phosphorylated mutant p53 observed in 
several cancer cell types, escapes the Murine Double 
Minute 2 protein (MDM2) and stabilizes in the tumor 
cells [39, 40], enabling them to evade cell death. However, 
the transient activation of wild type p53 in response to 
pharmacological stimulus or stress triggers a flexible 
cascade of gene expression that determines whether a cell 
type will undergo cell cycle arrest or programmed cell 
death [41–43]. Proteolytic cleavage of PARP by caspases 
is a universal phenomenon observed during programmed 
cell death induced by a variety of apoptotic stimuli 
including those that trigger activation of p53 [44–46]. It 
has thus been used in this study as a readout for evaluation 
of apoptotic cell death. Our results demonstrate that while 
the p53 defective MDA-MB-231 cells despite displaying 
profuse constitutive phosphorylation at the serine 
15 residue, show no decrease in intact PARP, the functional 
p53 in HUVEC undergo phosphorylation by 24 hr with 
an associated decrease or complete absence of full length 
PARP in response to either drug treatments, indicating 
that the sensitivity of different cell types to the two drugs 
is associated with the on activation/phosphorylation of 
p53. Based on this differential sensitivity of cell types 
contributing to the tumor formation, the nanotherapeutic 
strategy augmented by radiation exposure is so designed to 
target cytotoxic payloads of ATO and cisplatin that while 
increasing the dual drug concentration at the tumor site, 
will also create a microenvironment pernicious for survival 
of tumor cells. Efforts are now underway to delineate the 
p53-dependent and independent cell death/ damage via 
the intercellular crosstalk in response galectin-1 targeting 
in the tumor and its microenvironment utilizing our 3D 
TNBC tumor model [25].
Radiation-enhanced therapeutic targeting of 
galectin-1 in the murine TNBC model developed 
from orthotopic implant of 3D TTA in nude mice
The complex organization of tumor microen-
vironment has been shown to be a critical component 
of response to therapeutic interventions in cancer 
[31, 47–50]. The field of cancer therapy is therefore in 
the midst of a major paradigm shift from an approach 
primarily focused on tumor cell killing to strategies that 
also targets the tumor microenvironment [51]. Preclinical 
tumor models that more appropriately represent the 
tumor and the malignant stroma such as the 3D TNBC 
model that we have developed from TTA implants in 
athymic nude mice enhance the ability to study devise 
target-based therapeutic interventions. Our recent studies 
demonstrate targeting of irradiated tumor endothelial cells 
via radiation-induced stromal enrichment of Galectin-1 
using Anginex conjugated liposomes encapsulating ATO 
and cisplatin. The platinum-arsenic loaded liposomes are 
very stable and are designed to release the drug only when 
internalized and processed through receptor-mediated 
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endocytosis. Figure 6 illustrates the radiation enhanced 
tumor-targeting of anginex conjugated dual drug-(ATO 
and cisplatin) loaded liposomes using the murine tumor 
model that better represents the microenvironment and 
structural characteristics of TNBC. 
The combinatorial nanotherapeutic strategy 
inhibits tumor growth and metastasis in the 
murine tumor model for TNBC
The therapeutic targeting of anginex-conjugated 
(4 mg ATO/kg, 2.5 mg cisplatin /kg), non-conjugated (4 
mg ATO/kg, 2.5 mg cisplatin /kg) was evaluated in non-
irradiated and irradiated tumors (~200 mm3) originating 
from TTA implants in the mammary fat pad of athymic 
nude female mice. Empty liposomes administered to 
mice bearing irradiated tumors served as control. Our 
initial observations of TTA implanted orthotopically in 
the mammary fat pad of mice resulted in large tumors 
(~1500 mm3) with aggressive metastasis to the lungs. 
The rapid progression of the disease required the mice 
to be sacrificed within 20–24 days [25]. Expecting a 
similar outcome in tumor bearing mice when treated with 
vehicle alone we opted to leave this treatment group from 
the experiment designed to understand the response to a 
treatment regimen for ~3 weeks. Further, initiating the 
nanotherapeutic treatment regimen when the orthotopic 
tumors are ~200 mm3 (was also based on the rationale 
and our previous studies to ensure the formation of the 
tumor-associated stroma for targeting in the murine TNBC 
model [25]. While non-conjugated liposomes and anginex 
conjugated liposomes inhibited growth of irradiated 
and non-irradiated mammary tumors respectively by 
~40%, tumor growth was significantly reduced by ~80% 
in irradiated tumors treated with anginex-conjugated 
liposomes. The tumor growth in the non-irradiated mice 
treated with non-conjugated liposomes was reduced only 
~20% (Figure 7A–7B). Combined treatment of radiation 
and targeted nanoparticles was well tolerated by the 
mice with no significant difference in body weight when 
compared to radiation control (Figure 7C). 
The combinatorial nanotherapuetic strategy 
inhibits metastasis to the lung and results in 
increased accumulation of arsenic and cisplatin 
in the tumor tissue
Consistent with enhanced tumor efficacy, our 
study on invasion of the disease to distant organs 
revealed that metastasis to the lung was much reduced 
Figure 4: Radiation augmented galectin-1 expression in orthotopic tumors originating from TTA. (A) Representative 
images of immunohistochemistry for galectin-1 in benign breast tissue (BT), tumor tissue (TT) and irradiated tumor tissue (IT) originating 
from orthotopic implants of TTA in mice 72 hours post-radiation exposure of 2 Gy. (b) Galectin-1 staining was quantitated by APERIO® 
ImageScope and scored using the H-score approach as described in the methods and graphically represented. N = 3/group, *p < 0.0003 for 
TT vs IT, BT vs. IT and BT vs TT.
Figure 5: Sensitivity of HUVECs but not tumor cells to cisplatin and ATO is associated with phosphorylation of 
p53. MDA-MB-231 tumor cells and HUVECs were treated with 20 µM and 10 µM cisplatin and ATO respectively. Treatment with both 
drugs caused decrease in PARP expression and serine 15 phosphorylation of p53 in HUVECs but relatively no change in both in the 
MDA- MB- 231 cells.
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in the irradiated animals treated with the targeted 
liposomes (Figure 8A– 8B).In our previous study we 
have demonstrated an increased uptake of the targeted 
nanoparticle with higher accumulation of arsenic and 
cisplatin 24 hr post treatment by the irradiated tumor 
tissue in the orthotopic implants of the TTA in nude mice 
[25]. These results established the radiation-enhanced 
targeting of stromal galectin-1 by the anginex-conjugated 
nanoparticles in the murine tumor model for TNBC. 
In this study, using the same TNBC model we have 
quantified the arsenic and cisplatin accumulation in the 
tumor tissue at the completion of the treatment regimen by 
ICP-MS. While the uptake of both arsenic and cisplatin in 
the irradiated tumors of mice at the end of the treatment 
regimen with the anginex-conjugated nanoparticles is 
higher than with non-conjugated nanoparticles, it is not 
as significant (Figure 8C–8D). It is now a universally 
accepted fact that all nanoscale particulate carriers 
including targeted and passively targeted liposomes 
are distributed to the target cells via the same passive 
distribution mechanism, by means of the enhanced 
permeability and retention effect [52]. An increased uptake 
of targeted liposomes by the diseased tissue, occurs as a 
consequence of the increased receptor-mediated uptake 
of liposomes, containing the entrapped drug, by the target 
cell [53]. The significant increase in arsenic and cisplatin 
accumulation in the irradiated tumor tissue after a single 
dose of the anginex-conjugated nanoparticle is possibly 
owing to the relatively faster clearance of the non-targeted 
nanoparticles from the intratumoral space [25]. However, 
repeated dosing as in this study may have increased 
the accumulation of the non-conjugated nanoparticles 
without affecting the drug uptake by the target cell and 
the subsequent improvement in therapeutic response. 
We also observe higher accumulation of cisplatin in the 
tumor tissue (9 μg/g tissue or higher) at the completion 
of the treatment regimen of radiation in conjunction 
with targeted or non-targeted nanoparticles (Figure 8C). 
Cisplatin undergoes aquation to form [Pt(NH3)2Cl(OH2)]
+ 
and [Pt(NH3)2(OH2)2]
2+ once inside the cell, intercalating 
between the DNA strands forming the cisplatin-DNA 
adducts [54]. The half-life of free ATO on the other hand 
falls between 10–48 hr (Agency for Toxic Substance & 
Disease Registry, 2007) and therefore we observed a 
notably lower concentration of arsenic in tumor tissues 
(1–2 μg/g tissue) post-treatment (Figure 8D).
The tissue residence of arsenic and cisplatin at 
the end of the study in different organs of the treated 
Figure 6: A Schematic representation of radiation enhanced nanotherapeutic targeting in the orthotopic tumor 
originating from Tumor tissue analogs (TTA) recreating TNBC and its microenvironment.
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mice by ICP-MS showed a similar trend as observed in 
the tumor tissues of higher accumulation of cisplatin in 
comparison to arsenic (Supplementary Figure S3). The 
kidney and liver were sites with maximum residence 
of arsenic and cisplatin. ICP-MS analysis of the brain 
tissue revealed minimum accumulation of the two drugs. 
Restricted entry of most biomolecules by the blood brain 
barrier [55] and the glomerular kidney or sinusoidal 
liver capillaries forming the fenestrated vascular bed 
are the possible reasons for the respective low and high 
acquisition of arsenic and cisplatin in these organs [56]. 
Systemic toxicity during the treatments, was assessed 
by H&E staining of tissue sections from different organs 
of the experimental mice (Supplementary Figure S4). 
The H&E images indicated that all major organs after 
treatments maintained their typical structural phenotypes 
and did not exhibit appreciable microscopic lesions, 
further confirming the minimal side effects and acceptable 
biocompatibility.
dIscussIon
Compelling evidence gathered over recent decades 
indicate galectin-1, to be amongst the unique repertoire 
of proteins overexpressed across a spectrum of human 
cancers. These include breast [57], colon [58], lung 
[59], head & neck [60], ovarian [61] and prostrate [62] 
carcinomas in addition to gliomas [63], Kaposi’s sarcoma 
[64], myeloproliferative neoplasia [65] and Hodgkin 
lymphoma [66]. The overexpressed galectin-1 is localized 
both in the stroma surrounding the tumor cells and in the 
cancer associated endothelial cells [67–69]. Here we report 
Figure 7: The combinatorial nanotherapeutic strategy inhibits tumor growth with no significant change in body 
weight in the murine TNBC model. (A) Representative images of mammary tumors post treatment in female athymic nude mice with 
orthotopic implants of TTA. 14 days after surgical implantation of TTA in the mammary fat pad, mice were randomized into five treatment 
groups: Radiation + empty liposomes (3 Gy + vehicle), non-conjugated (ATO/cisplatin loaded) liposomes (Non-conjugated), Radiation 
+non-conjugated liposomes (3 Gy + Non-Conjugated), anginex-conjugated (ATO/cisplatin loaded) targeted liposomes (Ax-conjugated), 
Radiation + anginex-conjugated targeted liposomes (3 Gy + Ax-Conjugated). Agents were delivered 2 hrs post-radiation twice at an interval 
of 24 hr via tail vein injection and the regimen was repeated three times with a gap of 4 days as indicated. (b) Graphical representation of 
tumor growth in mice with orthotopic xenografts of TTA. (c) No significant weight loss was observed in any treatment group compared 
with radiation + vehicle-treated mice. Results indicated as mean ± SD (N = 3 mice/group). *p < 0.005 (vehicle vs non-conjugated and 
vehicle vs Ax-conjugated, non-conjugated vs ax-conjugated nanoparticle treatment with and without radiation).
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an elevated expression of galectin-1 in clinical samples 
from TNBC patients and data collected from the Human 
protein atlas on ductal carcinoma in women between the 
ages of 27–40 years (Figures 1 and 3). The galectin-1 
expression profile in tumor and benign tissue sections 
of ductal carcinomas was also comparable to VEGF, a 
multifunctional cytokine, most clinically exploited for 
vascular targeting in tumors (Figure 1). To develop a tumor 
specific galectin-1 targeting delivery system that enhances 
the effectiveness of the nanotherapeutics, it was essential 
for us to assess the differential expression of galectin-1 in 
normal and tumor tissue. In accordance with the results 
from studies on other cancer associated malignancies, we 
also found, galectin-1 to be consistently overexpressed 
in the tumor-associated stroma of TNBC patients with 
significantly lower expression in benign breast and normal 
tissues from other organs (Figures 1–3). The recruitment 
of endothelial cells to form new blood vessel is an 
important step in the development, invasion and metastatic 
colonization of proliferative neoplasms such as the TNBC 
[70]. The targeting of transformed tumor cells has several 
limitations owing to their inherent drug resistance and 
highly heterogeneous malignant cell population [47–49]. 
While most chemotherapy is capable of killing tumor 
cells efficiently, it lacks the ability for selective targeting 
[71, 72]. Conversely, many anti-angiogenic agents, while 
not able to control tumor growth, possess the ability to 
selectively target the location and process of tumor blood 
vessel formation [73, 74]. The current study capitalizes 
on the radiation enhanced targeting of the antiangiogenic, 
anginex peptide to the galectin-1 enriched tumor 
microvasculature [24, 75] and the existing technique of 
liposomal encapsulation of chemotherapy to design a 
novel therapeutic approach for selective and effective 
inhibition of tumor growth and metastasis in TNBC. 
Ongoing efforts in the laboratory are directed to perform 
in-depth investigations for understanding the mechanistic 
underpinnings of radiation-augmented galectin-1 surge 
in the 3D TTA that enable enhanced binding of anginex-
conjugated targeted liposomes.
While there are no specialized guidelines for 
TNBC treatment, single or multi-agent chemotherapy 
Figure 8: The combinatorial nanotherapeutic strategy results in inhibition of lung metastasis with increase in Arsenic 
and cisplatin accumulation in the murine tumor model for TNBC. (A) Representative images metastatic lesions in diseased 
lungs post treatment in female athymic nude mice with orthotopic implants of TTA randomized in three treatment groups: Radiation + 
empty liposomes (3 Gy + vehicle), Radiation +non-conjugated (ATO/cisplatin loaded) liposomes (3 Gy + Non-Conjugated), Radiation 
+ anginex-conjugated (ATO/cisplatin loaded) targeted liposomes (3 Gy + Ax-Conjugated). Agents were delivered 2 hrs post-radiation 
twice at an interval of 24 hr via tail vein injection and the regimen was repeated three times with a gap of 4 days as indicated. (b) Graphic 
representation of lung metastasis in mice bearing tumors originating from TTA implants. Results indicated as mean ± SD (N = 3 mice/ 
group).*p <  0.05 (vehicle vs non-conjugated and Ax-conjugated nanoparticle treatment). Athymic nude mice with orthotopic implants of 
TTA after completion of the 6 treatments in the treatment regimen were sacrificed and tumor tissues were analyzed for arsenic (c) and 
cisplatin (d) by ICP-MS. Results indicated as mean ± SD (N = 3 mice/group) with *p < 0.001 for for arsenic cisplatin acquisition at the end 
of the study in mice with irradiated tumors treated with vehicle vs non-conjugated and vehicle vs Ax-conjugated nanoparticle. The #p < 0.05 
was also significant for cisplatin but not arsenic uptake in irradiated mice treated with non-conjugated vs ax-conjugated nanoparticles.
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continues to remain the mainstay in the treatment of 
TNBC patients. Owing to concerns for significant toxicity, 
radiation when used is delivered sequentially following 
systemic chemotherapy. The benefits of radiation therapy 
in locoregional control and recurrence in breast cancer 
with improved survival [76] has sparked a recent interest 
to analyze the role of radiation in breast conserved 
therapy and locoregional recurrence in TNBC [77–79]. 
Interestingly, our studies have revealed a further induction 
of the stromal galectin-1 in response to radiation exposure 
in 2D, 3D and various preclinical tumor models [24, 25] 
and (Figure 4), indicating the possibility of combining 
radiation with targeted nanochemotherapy and reduced 
side effects. Furthermore, though ATO and cisplatin are 
identified as a synergistic drug combination in lung and 
squamous cell carcinomas [80, 81], the use of metal-
based cytotoxic agents in standard clinical treatments of 
tumors is currently limited because (i) they cause acute 
systemic toxicity and cannot be administered at effective 
concentrations, (ii) are unstable in circulation and (iii) 
are subject to multiple mechanisms of drug resistance. 
The co-encapsulation of these drugs in nanocarriers 
overcome most of these challenges. When bound to 
receptors for specific cell targeting these nanovesicles are 
at a further advantage, as they are taken up by receptor-
mediated endocytosis, thereby avoiding drug efflux by 
P-glycoprotein and overcoming drug resistance [82].
Evidence supports a major subgroup of TNBC 
originating from epithelial cells is genomically unstable 
with mutated p53 [83]. Our study using a p53 defective 
human epithelial TNBC cell line, MDA-MB-231 and a 
p53 functional human endothelial cell type, HUVEC, 
indicates the sensitivity to ATO and cisplatin in 
different human cell types to be regulated by activation/ 
phosphorylation of p53 phosphorylation (Figure 5) and is 
similar to the effect observed in our in vitro/in vivo 3D 
murine TNBC models [25]. This led us to design a two 
pronged active targeting strategy augmented by radiation 
exposure (Figure 6): that while increasing the dual drug 
concentration at the tumor site, creates a microenvironment 
unconducive for tumor cell survival. ATO encapsulated in 
nanovesicles was expected to facilitate effective tumor-
targeted delivery by causing vascular damage [84, 85] 
and overcoming resistance of tumor cells to conventional 
cisplatin chemotherapy. The controlled release of cisplatin 
from the tumor endothelium targeted liposomes was 
expected to further enhance the therapeutic efficacy 
of the drug delivery system by simulating the effect of 
low-dose metronomic chemotherapy [86]. In this study 
we investigate the therapeutic outcome of radiation 
enhanced tumor-targeting of nanosized ATO and cisplatin 
chemotherapy to the galectin-1 enriched malignant stroma. 
Data obtained from this study suggests the means to 
exploit clinically relevant radiation dose for concurrent 
receptor mediated enhanced delivery of chemotherapy 
while limiting overall toxicity (Figure 7). The minimal 
weight-loss and lack of observable signs of toxicity in 
organ histology associated with liposomal treatment in 
conjunction with radiation is attributed to the stability of 
the drug payload in physiological and acidic conditions, 
and so despite typical liposomal accumulation in the liver 
and other tissues there is minimal toxicity (Figure 7D). 
Since treatment options available for TNBC are limited, 
the ability of such a novel nanotherapeutic system to 
deliver combined therapy while limiting toxicity has the 
potential to improve survival outcome in TNBC patients 
and accelerate drug development.
MATERIALS AND METHODS
Cell lines and culture
4T1-mCherry is a red fluorescent protein-expressing 
murine metastatic mammary carcinoma cell line that closely 
mimics the triple negative subtype of human breast cancer 
[87]; was a kind gift from Dr. D. D. Schlaepfer (University 
of California, San Diego, CA). 2H11, murine tumor 
endothelial cell line [88], and C166-GFP, a murine green 
fluorescent protein-expressing endothelial cell line, were 
purchased from ATCC (Manassas, VA). Murine embryonic 
fibroblasts (MEF) were a kind gift from Dr. V. Rangnekar 
(University of Kentucky, Lexington, KY). The cell lines 
were routinely cultured in high glucose DMEM containing 
10% (v/v) fetal bovine serum and 100 IU/mL penicillin, 
100 IU/mL streptomycin at 37°C, 5% CO2, and 95%.
Chemicals and reagents
Arsenic [Arsenic (III) oxide] and Cisplatin [cis-
Diamineplatinum (II) dichloride] were purchased from 
Sigma-Aldrich, Inc. (St. Louis, MO). Anginex peptide 
was purchased from AAPPTEC (Louisville, KY). The 
antibodies, galectin-1 (Sigma #HPA000646) and (R&D 
AF-1152) were used for immunohistochemistry of 
clinical and murine tumor tissue samples respectively. 
The antibodies, p53 phospho (ser15) (#9284) and poly 
(ADP-ribose) polymerase [PARP] (#9532) for western 
immunoblotting were purchased from Cell Signaling 
Technology. Lipids used for liposome preparation were 
purchased from Avanti Polar Lipids (Alabaster, Al).
Tumor tissue analogs (TTA) for orthotopic 
implant in nude mice
4T1-mcherry tumor cells, C166-GFP endothelial 
cells and murine embryonic fibroblasts (MEF) were 
used to generated single or multicell type 3D cultures 
in “hanging drops” of media (Dulbecco modified Eagle 
medium with 10% fetal bovine serum and antibiotic 
mix) as previously described [50]. Briefly, single a cell 
suspension of 4T1-mcherry cells, C166-GFP cells and 
MEF cells in equal proportion (3000 cells/20 μL) was 
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dispensed on the inside of the lid of each well of a 48-well 
cell culture plate (Greiner Cellstar, BioExpress, Kaysville, 
UT). The growth of TTA was monitored over time until 
day 14 in a hanging drop of medium, following which 
they were subject to radiation exposure and treatment with 
liposomes. The 3D co-cultures/TTA were subsequently 
transferred to optically clear Greiner repellent plates for 
imaging and analysis of the treatment response over a 
period of 8–10 days.
Animals
All animal procedures were approved by the 
University of Kentucky Animal Institutional Care and 
Use Committee (IACUC). Female, athymic nude mice 
(Crl:NU(Ncr)-Foxn1nu) obtained from Charles River 
(6–12 weeks old, 20–22 gm) were purchased from 
Harlan’s Laboratories (Haslett, MI). All experimental mice 
were housed in sterile environmental conditions of the 
University of Kentucky’s Division of Laboratory Animal 
Resources (DLAR) and provided sterile food and water 
ad libitum. 
Orthotopic breast cancer model
Mice were anesthetized with isoflurane (1–4% 
vaporizer) or Ketamine/Xylazine, IP, 100/10 mg/kg 
respectively. Two TTA generated from 3D cultures of 
tumor cells, endothelial cells and fibroblasts as described 
in [25] were subcutaneously implanted by a small incision 
(2–4 mm) bilaterally into the fat pad of the 3rd mammary 
gland and sutured with tissue adhesive (3M VetBond, 
St. Paul, MN) Tumor growth was recorded by caliper 
measurement after a recovery period of 1–2 days. Mice 
were euthanized at study endpoint by isoflurane overdose. 
Tumor tissues and lungs were excised for further analysis.
Immunohistochemistry for galectin-1 expression 
In clinical samples of tumor and benign tissue 
fromTNBC patients
Six cases of triple negative breast cancer from 
formalin fixed surgical archives of the University of 
Kentucky were selected and 4-micron thick sections were 
cut from each and dried overnight at 58°C. Slides were 
deparaffinized and hydrated stepwise followed by heat-
induced epitope retrieval (HIER) in high pH antigen 
retrieval solution (Dako) at 110°C for 20 minutes using 
a Biocare Medical Decloaking Chamber. Slides were 
incubated in Galectin-1 antibody (Sigma #HPA000646) 
diluted at 1:400 for 30 minutes at room temperature 
followed by incubation with polymer bound anti-rabbit 
secondary for 30 minutes (Dako Envision+). Staining 
was visualized by incubation with 3, 3′-diaminobenzidine 
(DAB) chromogen (Dako, CA) for 3 minutes and slides 
were lightly counterstained with hematoxylin. 
In orthotopic tumors originating from TTA in 
athymic nude mice
Formalin fixed paraffin embedded tissue was 
sectioned at 4-microns and dried overnight at 58°C. Slides 
were deparaffinized and hydrated stepwise followed by 
heat-induced epitope retrieval (HIER) in high pH antigen 
retrieval solution (Dako) at 110°C for 20 minutes using 
a Biocare Medical Decloaking Chamber. Slides were 
incubated in Galectin-1 antibody (R&D AF-1152) diluted 
at 1:50 for one hour at room temperature followed by 
incubation with polymer bound anti-goat secondary for 
30 minutes (Vector Laboratories Immpress kit).  Staining 
was visualized by incubation with 3, 3′-diaminobenzidine 
(DAB) chromogen (Dako, CA) for 5 minutes and slides 
were lightly counterstained with hematoxylin.
Evaluation and quantification of 
immunohistochemistry
All slides were digitalized on an APERIO® 
ScanScope (Leica Biosystems) and were evaluated on 
an APERIO® ImageScope (Leica Biosystems)using the 
positive pixel counting algorithm, which scores the stains 
as negative, weak-positive, medium, and strong. This 
algorithm also measures the percentage of positivity by 
area and the average intensity of positive staining. HScore 
for each case of benign and tumor tissue sample from 
TNBC patient, based on the percentage and intensity of 
staining was determined. HScore takes into consideration 
the intensity of the staining and the percentage of 
positive cells per the formula: HScore = 1 × (% light 
staining) + 2 × (% moderate staining) + 3 × (% strong 
staining). HScores range from 0 to 300 [89].
Hematoxylin and eosin staining and imaging
Hematoxylin and eosin (H&E) staining was 
performed by staining the cryostat sections of TES 
with Harris hematoxylin (aluminum potassium sulfate, 
hematoxylin, absolute alcohol, mercuric oxide, and 
glacial acetic acid) followed by 1% acid alcohol and, 
subsequently, 1% eosin. Images were taken at 40X 
magnification using a Nikon Ti E upright microscope 
with a Cool SNAP HQ2 CCD camera (Tokyo, Japan) and 
processed with NIS-Elements basic research software. 
Tumor/Cell X−Ray irradiation
Radiation exposure was given using the Varian 
TrueBeam System (Varian medical systems, Palo 
Alto, CA) X-Ray machine set at a radiation dose rate 
1.018 ± 0.10 Gy/ min at 150 kV and 6.6 mA. Typical 
radiation exposure in all experiments was at 3 Gy. Mice were 
anesthetized with Ketamine/Xylazine, IP, 100/10 mg/ kg, and 
radiation was administered with a custom cut lead shielding 
covering the animal, except for the tumor-bearing region. 
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Whole cell lysates and immunoblot analysis
Whole cell extracts were prepared by suspending 
cells in 0.25 ml of lysis buffer (25 mM HEPES, pH 7.5, 
0.5% 498 J Mol Med (2013) 91:497–506 sodium 
deoxycholate, 5 mM EDTA, 5 mM dithiothreitol, 
20 mM glycerophosphate, 1 mM Na3VO4, 50 mM 
NaF, 1% Triton X-100, 20 μg/ml aprotinin, 50 μg/ ml 
leupeptin, 10 μM pepstatin, 1 μM okadaic acid, and 
1 mM phenylmethylsulfonyl fluoride). The lysates were 
incubated at 4°C with gentle agitation on a rocker plate 
(Mini Mixer, Benchmark Research Products, NY) for 1 h 
and cell debris was removed by centrifugation (15 min at 
12,000 × g). The protein concentration in the supernatant 
was determined usingthe bicinchoninic acid (BCA) protein 
assay kit (Pierce). Immunoblotting was performed using 
30 µg of protein/lane and standard polyvinylidene fluoride 
membrane transfer followed by probing with the respective 
antibody and chemiluminescent detection of bands.
Synthesis and characterization of Anginex-
conjugated liposomes
The untargeted liposomes were synthesized using 
the aquo-cisplatin concentration gradient as previously 
described [90]. In these studies, untargeted liposomes 
were comprised of disteroylphospatidyl choline, 
cholesterol, and distearoylphosphatidyl ethanolamine-
mPEG2000 at a molar ratio of 0.5/0.46/0.04, respectively, 
with additional 0.1 mol% DiD (1,1′-Dioctadecyl-3,3,3′,3′-
Tetramethylindodicarbocyanine Perchlorate) fluorescent 
dye (Life Technology). The lipids were produced at large 
scale using techniques described previously [91, 92] 
Anginex-azide was synthesized by modifying the protein 
at the N-terminus using azide-dPEG4-NHS (Quanta 
Biodesign). Alkyne functional lipids were synthesized 
and inserted into pre-formed liposomes as previously 
described [92]. Anginex-azide was reacted with the 
alkyne-liposomes at 25-fold molar excess compared to 
concentration of liposomes. Unconjugated anginex was 
removed by tangential flow filtration. Phospholipid, 
arsenic and platinum concentration was determined by 
ICP-OES and particle size was measured by dynamic 
light scattering (Malvern Zetasizer). Nanob were 
characterized by ICP-OES, using a matrix of 3% nitric 
acid, 2% acetic acid and water. Details are provided in 
the methods described earlier [25]. Briefly, the liposomes 
were diluted into matrix, then analysed by ICP-OES. 
Size was determined by dynamic light scattering in the 
Keck Biophysics Core Facility, using a 514 nm laser 
equipped with a Brookhaven BI-200 goniometer and 
BI-9000 high speed correlator. The modification of the 
liposome formulation with anginex to target galectin-1 
overexpressed on irradiated endothelial cell surface occurs 
in three convergent steps. First, the anginex is modified 
with a heterobifunctional crosslinker containing an azide 
group. Next, drug-loaded liposomes are modified with 
an alkyne-containing lipid molecule, creating alkyne-
modified reactive liposomes. The alkyne liposomes and 
the azide Anginex are then cross-linked using a copper-
catalyzed alkyne-azide cycloaddition “click” reaction [25]. 
The resulting liposomes are stable at 4°C for 6 months 
without aggregating, precipitating or loosing therapeutic 
potency. Drug release from the liposomes is triggered by 
thiol-containing compounds, such as glutathione.
Tail vein injection
The animals were anesthetized as described above. 
DID [Dioctadecyl-tetramethylindodicarbocyanine] 
labeled liposomes (4 mg ATO/kg, 2.5 mg cisplatin/kg) 
were administered at a volume of 150–200 µl with a 
27 G needle in the lateral tail vein of mice bearing the 
subcutaneous mammary fat pad tumors ~200 mm3 in size.
Inductively coupled plasma-mass spectrometry
The quantitative analysis of Platinum and Arsenic 
in tumor tissue samples of tumors and other organs was 
accomplished via ICP-MS of acid digested samples using 
a Thermo XSeries II ICP-MS (Thermo-Fisher Scientific, 
Waltham, MA) as described [91]. Briefly, Platinum and 
Arsenic quantification in tumor tissues was accomplished 
via ICP-MS of acid digested samples using a Thermo 
XSeries II ICP-MS (Thermo-Fisher Scientific, Waltham, 
MA). Specifically, samples were prepared by adding 
200 µL of nitric acid (HNO3, 70%, Aristar Plus Grade, 
BDH) and 50 µL of hydrochloric acid (30%, Aristar Plus 
Grade, BDH) to pre-weighed tissues and incubated at 80°C 
for 8 hrs for complete sample digestion. Multi-element 
internal standard (Inorganic Ventures, Christiansburg, VA) 
and filtered deionized H2O (18.2 MΩ·cm) were added, 
producing a final ICP-MS sample of 4% (v/v) HNO3, 1% 
HCl, and 5 ng/mL multi-element internal standard.
Statistical analysis
Data are summarized as mean ± SD for each 
experimental group.  Two-sample t-test or analysis of 
variance was employed for two-group and multiple group 
comparisons, respectively, with contrast generated from 
the ANOVA model to perform pairwise comparisons. 
Paired t-test was employed for comparison of Galectin-1 
H-score for paired normal and tumor samples.  Finally, 
linear mixed model was employed for comparison 
of tumor volume over time. Statistical analysis was 
performed using SAS version 9.4.
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